{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:44:21Z","timestamp":1788252261490,"version":"build-2803163510"},"reference-count":196,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.ijbiomac.2022.11.031","type":"journal-article","created":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T20:50:05Z","timestamp":1667854205000},"page":"143-160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"special_numbering":"PA","title":["Protein misfolding and related human diseases: A comprehensive review of toxicity, proteins involved, and current therapeutic strategies"],"prefix":"10.1016","volume":"223","author":[{"given":"Asra Nasir","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rizwan Hasan","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0005","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1146\/annurev.genom.7.080505.115737","article-title":"Protein misfolding and human disease","volume":"7","author":"Gregersen","year":"2006","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0010","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1021\/bi00327a032","article-title":"Theory for the folding and stability of globular proteins","volume":"24","author":"Dill","year":"1985","journal-title":"Biochemistry"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0015","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1017\/S0033583508004654","article-title":"Protein folding and misfolding: mechanism and principles","volume":"40","author":"Englander","year":"2007","journal-title":"Q. Rev. Biophys."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0020","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1146\/annurev-biochem-061516-044518","article-title":"Protein misfolding diseases","volume":"86","author":"Hartl","year":"2017","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0025","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.cell.2012.02.022","article-title":"The amyloid state of proteins in human diseases","volume":"148","author":"Eisenberg","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0030","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1073\/pnas.96.7.3590","article-title":"Designing conditions for in vitro formation of amyloid protofilaments and fibrils","volume":"96","author":"Chiti","year":"1999","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.0060195","article-title":"Bacterial inclusion bodies contain amyloid-like structure","volume":"6","author":"Wang","year":"2008","journal-title":"PLoS Biol."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0040","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1126\/science.1178250","article-title":"An analytical solution to the kinetics of breakable filament assembly","volume":"326","author":"Knowles","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0045","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1006\/jsbi.2000.4221","article-title":"Review: history of the amyloid fibril","volume":"130","author":"Sipe","year":"2000","journal-title":"J. Struct. Biol."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0050","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/nature02264","article-title":"Folding proteins in fatal ways","volume":"426","author":"Selkoe","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0055","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1159\/000506696","article-title":"The pathology of amyloidosis in classification: a review","volume":"143","author":"Picken","year":"2020","journal-title":"Acta Haematol."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0060","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.bbadis.2011.10.002","article-title":"\u0391-synuclein misfolding and Parkinson\u2019s disease","volume":"1822","author":"Breydo","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0065","doi-asserted-by":"crossref","first-page":"6445","DOI":"10.1021\/bi400442d","article-title":"Interaction of 14\u20133-3\u03b6 with microtubule-associated protein tau within Alzheimer\u2019s disease neurofibrillary tangles","volume":"52","author":"Qureshi","year":"2013","journal-title":"Biochemistry"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0070","doi-asserted-by":"crossref","DOI":"10.1103\/PhysRevE.80.051907","article-title":"Model for amorphous aggregation processes","volume":"80","author":"Stranks","year":"2009","journal-title":"Phys. Rev. E"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0075","doi-asserted-by":"crossref","first-page":"5942","DOI":"10.1111\/j.1742-4658.2005.05024.x","article-title":"Aspects on human amyloid forms and their fibril polypeptides","volume":"272","author":"Westermark","year":"2005","journal-title":"FEBS J."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0080","doi-asserted-by":"crossref","first-page":"18728","DOI":"10.1038\/srep18728","article-title":"Quantitative analysis of intrinsic and extrinsic factors in the aggregation mechanism of alzheimer-associated A\u03b2-peptide","volume":"6","author":"Meisl","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0085","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1524128113","article-title":"Kinetic model of the aggregation of alpha-synuclein provides insights into prion-like spreading","volume":"113","author":"Iljina","year":"2016","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0090","doi-asserted-by":"crossref","first-page":"7025","DOI":"10.1038\/ncomms8025","article-title":"A mechanistic model of tau amyloid aggregation based on direct observation of oligomers","volume":"6","author":"Shammas","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0095","doi-asserted-by":"crossref","DOI":"10.1098\/rsfs.2017.0030","article-title":"Factors affecting the physical stability (aggregation) of peptide therapeutics","volume":"7","author":"Zapadka","year":"2017","journal-title":"Interface Focus"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0100","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.sbi.2017.01.004","article-title":"Exploring the relationships between protein sequence, structure and solubility","volume":"42","author":"Trainor","year":"2017","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0105","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/nature01891","article-title":"Rationalization of the effects of mutations on peptide andprotein aggregation rates","volume":"424","author":"Chiti","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0110","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1042\/bse0560041","article-title":"Predicting aggregation-prone sequences in proteins","volume":"56","author":"De Baets","year":"2014","journal-title":"Essays Biochem."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0115","doi-asserted-by":"crossref","first-page":"10816","DOI":"10.1038\/ncomms10816","article-title":"Structural hot spots for the solubility of globular proteins","volume":"7","author":"Ganesan","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0120","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.3390\/ijms20163896","article-title":"Causative links between protein aggregation and oxidative stress: a review","volume":"20","author":"L\u00e9vy","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0125","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/316523","article-title":"Oxidative stress and the pathogenesis of Alzheimer\u2019s disease","volume":"2013","author":"Zhao","year":"2013","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0130","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fnana.2015.00091","article-title":"Oxidative stress and Parkinson\u2019s disease","volume":"9","author":"Blesa","year":"2015","journal-title":"Front. Neuroanat."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0135","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3233\/JAD-2010-1239","article-title":"Increased iron and free radical generation in preclinical alzheimer disease and mild cognitive impairment","volume":"19","author":"Smith","year":"2010","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0140","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13018-017-0578-z","article-title":"In vivo evaluation of microglia activation by intracranial iron overload in central pain after spinal cord injury","volume":"12","author":"Meng","year":"2017","journal-title":"J. Orthop. Surg. Res."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0145","doi-asserted-by":"crossref","first-page":"12052","DOI":"10.1074\/jbc.M113.525212","article-title":"\u03b2-amyloid fibrils in alzheimer disease are not inert when bound to copper ions but can degrade hydrogen peroxide and generate reactive oxygen species","volume":"289","author":"Mayes","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0150","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/j.jmb.2019.01.018","article-title":"Metal toxicity links to Alzheimer\u2019s disease and neuroinflammation","volume":"431","author":"Huat","year":"2019","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0155","first-page":"5073","article-title":"Arsenite interferes with protein folding and triggers formation of protein aggregates in yeast","volume":"125","author":"Jacobson","year":"2012","journal-title":"J. Cell Sci."},{"issue":"Suppl 4","key":"10.1016\/j.ijbiomac.2022.11.031_bb0160","doi-asserted-by":"crossref","first-page":"16419","DOI":"10.1073\/pnas.212527999","article-title":"Studies of the aggregation of mutant proteins in vitro provide insights into the genetics of amyloid diseases","volume":"99","author":"Chiti","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0165","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the alpha-synuclein gene identified in families with Parkinson\u2019s disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0170","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1212\/WNL.0b013e318221acd3","article-title":"PLA2G6 gene mutation in autosomal recessive early-onset parkinsonism in a chinese cohort","volume":"77","author":"Shi","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0175","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2014.117","article-title":"Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies","volume":"47","author":"Ciechanover","year":"2015","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0180","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1046\/j.1471-4159.2000.0750436.x","article-title":"Impaired proteasome function in Alzheimer\u2019s disease","volume":"75","author":"Keller","year":"2000","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0185","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/35086067","article-title":"Failure of the ubiquitin-proteasome system in Parkinson\u2019s disease","volume":"2","author":"McNaught","year":"2001","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0190","doi-asserted-by":"crossref","first-page":"12924","DOI":"10.1074\/jbc.M306390200","article-title":"Proteasomal inhibition by alpha-synuclein filaments and oligomers","volume":"279","author":"Lindersson","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0195","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.brainres.2008.03.003","article-title":"Amyloid peptides in different assembly states and related effects on isolated and cellular proteasomes","volume":"1209","author":"Cecarini","year":"2008","journal-title":"Brain Res."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0200","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/s41467-018-03509-0","article-title":"A common mechanism of proteasome impairment by neurodegenerative disease-associated oligomers","volume":"9","author":"Thibaudeau","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0205","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.cell.2010.05.008","article-title":"Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by alzheimer-related PS1 mutations","volume":"141","author":"Lee","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0210","doi-asserted-by":"crossref","first-page":"871","DOI":"10.4161\/auto.6.7.13286","article-title":"The PINK1\/Parkin-mediated mitophagy is compromised by PD-associated mutations","volume":"6","author":"Geisler","year":"2010","journal-title":"Autophagy"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0215","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2020.00037","article-title":"Protein aggregation and dysfunction of autophagy-lysosomal pathway: a vicious cycle in lysosomal storage diseases","volume":"13","author":"Monaco","year":"2020","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0220","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1146\/annurev.biochem.75.101304.123901","article-title":"Protein misfolding, functional amyloid, and human disease","volume":"75","author":"Chiti","year":"2006","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0225","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/nature02264","article-title":"Folding proteins in fatal ways","volume":"426","author":"Selkoe","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0230","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.642623","article-title":"Membrane interactions and toxicity by misfolded protein oligomers","volume":"9","author":"Gonzalez-Garcia","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0235","first-page":"1625","article-title":"Amyloid growth and membrane damage: current themes and emerging perspectives from theory and experiments on A\u03b2 and hIAPP","volume":"2018","author":"Sciacca","year":"1860","journal-title":"Biochim. Biophys. Acta - Biomembr."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0240","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1007\/s00018-018-2854-4","article-title":"Mechanisms of protein toxicity in neurodegenerative diseases","volume":"75","author":"Chung","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0245","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1073\/pnas.1221292110","article-title":"Extensive changes in DNA methylation are associated with expression of mutant huntingtin","volume":"110","author":"Ng","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0250","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1073\/pnas.0308512100","article-title":"Incipient Alzheimer\u2019s disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses","volume":"101","author":"Blalock","year":"2004","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0255","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/mds.20573","article-title":"Genomic convergence to identify candidate genes for parkinson disease: SAGE analysis of the substantia nigra","volume":"20","author":"Noureddine","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0260","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1074\/jbc.M606202200","article-title":"A ganglioside-induced toxic soluble abeta assembly. Its enhanced formation from abeta bearing the Arctic mutation","volume":"282","author":"Yamamoto","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0265","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.3233\/JAD-2012-129001","article-title":"Molecular mechanisms of amyloid oligomers toxicity","volume":"33","author":"Kayed","year":"2012","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0270","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1016\/j.bbamem.2007.02.002","article-title":"The redox chemistry of the Alzheimer\u2019s disease amyloid beta peptide","volume":"1768","author":"Smith","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/795375","article-title":"Amyloid Beta: multiple mechanisms of toxicity and only some protective effects?","volume":"2014","author":"Carrillo-Mora","year":"2014","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0280","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0197-0186(01)00012-2","article-title":"Glutathione elevation and its protective role in acrolein-induced protein damage in synaptosomal membranes: relevance to brain lipid peroxidation in neurodegenerative disease","volume":"39","author":"Pocernich","year":"2001","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0285","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0891-5849(91)90192-6","article-title":"Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes","volume":"11","author":"Esterbauer","year":"1991","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0290","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/S0891-5849(02)00794-3","article-title":"Lipid peroxidation and protein oxidation in Alzheimer\u2019s disease brain: potential causes and consequences involving amyloid \u03b2-peptide-associated free radical oxidative stress 1,2 1Guest Editors: Mark A. Smith and George Perry 2This article is part of a ser","volume":"32","author":"Butterfield","year":"2002","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0295","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s11814-012-0060-x","article-title":"Techniques for monitoring protein misfolding and aggregation in vitro and in living cells","volume":"29","author":"Gregoire","year":"2012","journal-title":"Korean J. Chem. Eng."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0300","article-title":"A guide to studying protein aggregation","author":"Housmans","year":"2021","journal-title":"FEBS J."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0305","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.bpj.2012.07.008","article-title":"Binding of Congo red to amyloid protofibrils of the alzheimer A\u03b2(9\u201340) peptide probed by molecular dynamics simulations","volume":"103","author":"Wu","year":"2012","journal-title":"Biophys. J."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0310","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3109\/10520291003784493","article-title":"A review of amyloid staining: methods and artifacts","volume":"86","author":"Fernandez-Flores","year":"2011","journal-title":"Biotech. Histochem."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0315","article-title":"ANS fluorescence: potential to discriminate hydrophobic sites of proteins in solid states","volume":"24","author":"Guliyeva","year":"2020","journal-title":"Biochem. Biophys. Rep."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0320","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054541","article-title":"Simultaneous measurement of amyloid fibril formation by dynamic light scattering and fluorescence reveals complex aggregation kinetics","volume":"8","author":"Streets","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0325","doi-asserted-by":"crossref","DOI":"10.1063\/1.3592581","article-title":"The use of dynamic light scattering and brownian microscopy to characterize protein aggregation","volume":"82","author":"Li","year":"2011","journal-title":"Rev. Sci. Instrum."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0330","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/bmb.20644","article-title":"Protein analysis by dynamic light scattering: methods and techniques for students","volume":"40","author":"Lorber","year":"2012","journal-title":"Biochem. Mol. Biol. Educ."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0335","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ymeth.2004.03.012","article-title":"Techniques to study amyloid fibril formation in vitro","volume":"34","author":"Nilsson","year":"2004","journal-title":"Methods"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0340","doi-asserted-by":"crossref","first-page":"11612","DOI":"10.1074\/jbc.M210207200","article-title":"In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis","volume":"278","author":"Stine","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0345","series-title":"Encycl. Spectrosc. Spectrom","first-page":"740","article-title":"Protein structure analysis by CD, FTIR, and Raman spectroscopies","author":"Tranter","year":"2017"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0350","first-page":"2339","article-title":"FTIR spectroscopic imaging of protein aggregation in living cells","volume":"2013","author":"Miller","year":"1828","journal-title":"Biochim. Biophys. Acta - Biomembr."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0355","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/10904","article-title":"Rapid protein-folding assay using green fluorescent protein","volume":"17","author":"Waldo","year":"1999","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0360","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1021\/cb600135w","article-title":"A high-throughput screen for compounds that inhibit aggregation of the Alzheimer\u2019s peptide","volume":"1","author":"Kim","year":"2006","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0365","first-page":"2515","article-title":"Tetrazolium-based assays for cellular viability: a critical examination of selected parameters affecting formazan production","volume":"51","author":"Vistica","year":"1991","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0370","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12551-021-00778-w","article-title":"Protein aggregation: in silico algorithms and applications","volume":"13","author":"Prabakaran","year":"2021","journal-title":"Biophys. Rev."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0375","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/325733a0","article-title":"The precursor of Alzheimer\u2019s disease amyloid A4 protein resembles a cell-surface receptor","volume":"325","author":"Kang","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0380","doi-asserted-by":"crossref","first-page":"R135","DOI":"10.1093\/hmg\/ddh077","article-title":"Alzheimer\u2019s disease: one disorder, too many genes?","volume":"13 Spec No","author":"Bertram","year":"2004","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0385","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.cell.2013.08.035","article-title":"Molecular structure of \u03b2-amyloid fibrils in Alzheimer\u2019s disease brain tissue","volume":"154","author":"Lu","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0390","doi-asserted-by":"crossref","first-page":"17342","DOI":"10.1073\/pnas.0506723102","article-title":"3D structure of Alzheimer\u2019s amyloid- (1\u201342) fibrils","volume":"102","author":"Luhrs","year":"2005","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0395","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/aps.2017.28","article-title":"Amyloid beta: structure, biology and structure-based therapeutic development","volume":"38","author":"Chen","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0400","doi-asserted-by":"crossref","DOI":"10.1063\/1.4921071","article-title":"In vitro fibrillization of Alzheimer\u2019s amyloid-\u03b2 peptide (1\u201342)","volume":"5","author":"Tiiman","year":"2015","journal-title":"AIP Adv."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0405","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/psc.2513","article-title":"Effect of agitation on the peptide fibrillization: Alzheimer\u2019s amyloid- \u03b2 peptide 1\u201342 but not amylin and insulin fibrils can grow under quiescent conditions","volume":"19","author":"Tiiman","year":"2013","journal-title":"J. Pept. Sci."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0410","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1146\/annurev-pathol-011110-130242","article-title":"Parkinson\u2019s disease: genetics and pathogenesis","volume":"6","author":"Shulman","year":"2011","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0415","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1073\/pnas.95.11.6469","article-title":"Alpha-synuclein in filamentous inclusions of lewy bodies from Parkinson\u2019s disease and dementia with lewy bodies","volume":"95","author":"Spillantini","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0420","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1136\/jnnp.51.6.745","article-title":"The relevance of the lewy body to the pathogenesis of idiopathic Parkinson\u2019s disease","volume":"51","author":"Gibb","year":"1988","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0425","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrn3406","article-title":"The many faces of \u03b1-synuclein: from structure and toxicity to therapeutic target","volume":"14","author":"Lashuel","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0430","doi-asserted-by":"crossref","first-page":"32486","DOI":"10.1074\/jbc.M110.139576","article-title":"Membrane curvature induction and tubulation are common features of synucleins and apolipoproteins","volume":"285","author":"Varkey","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0435","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13024-019-0329-1","article-title":"Alpha-synuclein structure and Parkinson\u2019s disease \u2013 lessons and emerging principles","volume":"14","author":"Meade","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0440","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nature16531","article-title":"Structural disorder of monomeric \u03b1-synuclein persists in mammalian cells","volume":"530","author":"Theillet","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0445","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nature10324","article-title":"\u03b1-synuclein occurs physiologically as a helically folded tetramer that resists aggregation","volume":"477","author":"Bartels","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0450","doi-asserted-by":"crossref","first-page":"E4","DOI":"10.1038\/nature12125","article-title":"Properties of native brain \u03b1-synuclein","volume":"498","author":"Burr\u00e9","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0455","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jpha.2022.04.001","article-title":"Human islet amyloid polypeptide: a therapeutic target for the management of type 2 diabetes mellitus","volume":"12","author":"Roham","year":"2022","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0460","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3390\/molecules27031021","article-title":"Molecular mechanisms of amylin turnover, misfolding and toxicity in the pancreas","volume":"27","author":"Bhowmick","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0465","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1210\/me.2004-0407","article-title":"Processing of pro-islet amyloid polypeptide in the constitutive and regulated secretory pathways of \u03b2 cells","volume":"19","author":"Marzban","year":"2005","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0470","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2174\/1389450053174596","article-title":"Pancreatic amylin as a centrally acting satiating hormone","volume":"6","author":"Lutz","year":"2005","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0475","doi-asserted-by":"crossref","first-page":"5036","DOI":"10.1073\/pnas.87.13.5036","article-title":"Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation","volume":"87","author":"Westermark","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0480","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/s41594-020-0435-3","article-title":"Cryo-EM structure and inhibitor design of human IAPP (amylin) fibrils","volume":"27","author":"Cao","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0485","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1084\/jem.20161134","article-title":"Induction of IAPP amyloid deposition and associated diabetic abnormalities by a prion-like mechanism","volume":"214","author":"Mukherjee","year":"2017","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0490","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2020.00035","article-title":"Islet amyloid polypeptide: a partner in crime with A\u03b2 in the pathology of Alzheimer\u2019s disease","volume":"13","author":"Raimundo","year":"2020","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0495","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s00125-006-0206-7","article-title":"Intracellular amyloid-like deposits contain unprocessed pro-islet amyloid polypeptide (proIAPP) in beta cells of transgenic mice overexpressing the gene for human IAPP and transplanted human islets","volume":"49","author":"Paulsson","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0500","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2015.00216","article-title":"Amylin at the interface between metabolic and neurodegenerative disorders","volume":"9","author":"Lutz","year":"2015","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0505","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/ana.23956","article-title":"Amylin deposition in the brain: a second amyloid in alzheimer disease?","volume":"74","author":"Jackson","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0510","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1326-9-30","article-title":"Neuroinflammation and neurologic deficits in diabetes linked to brain accumulation of amylin","volume":"9","author":"Srodulski","year":"2014","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0515","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1021\/acschemneuro.5b00192","article-title":"Cross-seeding interaction between \u03b2-amyloid and human islet amyloid polypeptide","volume":"6","author":"Hu","year":"2015","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0520","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1021\/ar050070g","article-title":"Normal and aberrant biological self-assembly: insights from studies of human lysozyme and its amyloidogenic variants","volume":"39","author":"Dumoulin","year":"2006","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0525","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/B978-0-12-386483-3.00003-3","article-title":"Lysozyme: a model protein for amyloid research","volume":"84","author":"Swaminathan","year":"2011","journal-title":"Adv. Protein Chem. Struct. Biol."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0530","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1021\/bm0498979","article-title":"Guanidine hydrochloride can induce amyloid fibril formation from hen egg-white lysozyme","volume":"5","author":"Vernaglia","year":"2004","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0535","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/385787a0","article-title":"Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis","volume":"385","author":"Booth","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0540","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ejmech.2018.02.035","article-title":"Secretase inhibitors for the treatment of Alzheimer\u2019s disease: long road ahead","volume":"148","author":"Kumar","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0545","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0550","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s13311-014-0325-7","article-title":"Drug repositioning approaches for the discovery of new therapeutics for Alzheimer\u2019s disease","volume":"12","author":"Kim","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0555","doi-asserted-by":"crossref","DOI":"10.4155\/fso.15.73","article-title":"The case of galantamine: repurposing and late blooming of a cholinergic drug","volume":"1","author":"Mucke","year":"2015","journal-title":"Futur. Sci. OA"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0560","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2174\/1567205016666190228123923","article-title":"Synthesis of new galanthamine-peptide derivatives designed for prevention and treatment of Alzheimer\u2019s disease","volume":"16","author":"Vezenkov","year":"2019","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0565","article-title":"Amantadine in Parkinson\u2019s disease","author":"Crosby","year":"2003","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0570","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3390\/ph11020044","article-title":"Old drugs as new treatments for neurodegenerative diseases","volume":"11","author":"Dur\u00e3es","year":"2018","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0575","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1741-7015-11-81","article-title":"Striking reduction of amyloid plaque burden in an Alzheimer\u2019s mouse model after chronic administration of carmustine","volume":"11","author":"Hayes","year":"2013","journal-title":"BMC Med."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0580","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2147\/NDT.S61309","article-title":"The emerging role of bexarotene in the treatment of Alzheimer\u2019s disease: current evidence","volume":"11","author":"Tousi","year":"2015","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0585","article-title":"Tamoxifen for amyotrophic lateral sclerosis: a randomized double-blind clinical trial","volume":"99","author":"Chen","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0590","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/jnr.10611","article-title":"Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by abeta and iron","volume":"72","author":"Perry","year":"2003","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0595","doi-asserted-by":"crossref","first-page":"6587","DOI":"10.1523\/JNEUROSCI.0529-11.2011","article-title":"The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer\u2019s disease","volume":"31","author":"McClean","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0600","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3233\/JAD-130584","article-title":"The neuroprotection of liraglutide on alzheimer-like learning and memory impairment by modulating the hyperphosphorylation of tau and neurofilament proteins and insulin signaling pathways in mice","volume":"37","author":"Xiong","year":"2013","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0605","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3233\/JPD-171192","article-title":"Is exenatide a treatment for Parkinson\u2019s disease?","volume":"7","author":"Athauda","year":"2017","journal-title":"J. Parkinsons. Dis."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0610","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2018.00224","article-title":"Can an infection hypothesis explain the Beta amyloid hypothesis of Alzheimer\u2019s disease?","volume":"10","author":"Fulop","year":"2018","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0615","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/j.jalz.2018.06.3040","article-title":"The antimicrobial protection hypothesis of Alzheimer\u2019s disease","volume":"14","author":"Moir","year":"2018","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0620","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awz244","article-title":"Time to test antibacterial therapy in Alzheimer\u2019s disease","author":"Panza","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0625","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1176\/ajp.156.3.467","article-title":"Improved cognition in Alzheimer\u2019s disease with short-term D-cycloserine treatment","volume":"156","author":"Tsai","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0630","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.00738","article-title":"Doxycycline for Alzheimer\u2019s disease: fighting \u03b2-amyloid oligomers and neuroinflammation","volume":"10","author":"Balducci","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0635","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/pcn.12637","article-title":"Therapeutic role of rifampicin in Alzheimer\u2019s disease","volume":"72","author":"Yulug","year":"2018","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0640","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/brain\/aww042","article-title":"Rifampicin is a candidate preventive medicine against amyloid-\u03b2 and tau oligomers","volume":"139","author":"Umeda","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0645","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1532-5415.2004.52109.x","article-title":"A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer\u2019s disease","volume":"52","author":"Loeb","year":"2004","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0650","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.bcp.2017.04.004","article-title":"Natural product-based amyloid inhibitors","volume":"139","author":"Velander","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0655","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/978-3-319-18365-7_4","article-title":"Natural phenolic compounds as therapeutic and preventive agents for cerebral amyloidosis","volume":"863","author":"Yamada","year":"2015","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0660","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1074\/jbc.M404751200","article-title":"Curcumin inhibits formation of amyloid \u03b2 oligomers and fibrils, binds plaques, and reduces amyloid in vivo","volume":"280","author":"Yang","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2019.146476","article-title":"The effect of curcumin on cognition in Alzheimer\u2019s disease and healthy aging: a systematic review of pre-clinical and clinical studies","volume":"1725","author":"Voulgaropoulou","year":"2019","journal-title":"Brain Res."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0670","doi-asserted-by":"crossref","first-page":"7710","DOI":"10.1073\/pnas.0910723107","article-title":"EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity","volume":"107","author":"Bieschke","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0675","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00392-012-0463-z","article-title":"Green tea halts progression of cardiac transthyretin amyloidosis: an observational report","volume":"101","author":"Kristen","year":"2012","journal-title":"Clin. Res. Cardiol."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0680","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3390\/life12030330","article-title":"Impact of caffeine on Alzheimer\u2019s disease pathogenesis\u2014protective or risk factor?","volume":"12","author":"Schreiner","year":"2022","journal-title":"Life"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0685","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20081829","article-title":"Recent developments in metal-based drugs and chelating agents for neurodegenerative diseases treatments","volume":"20","author":"Sales","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0690","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/472932","article-title":"Antioxidant therapies for Alzheimer\u2019s disease","volume":"2012","author":"Feng","year":"2012","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0695","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1096\/fj.03-0961fje","article-title":"Early vitamin E supplementation in young but not aged mice reduces abeta levels and amyloid deposition in a transgenic model of Alzheimer\u2019s disease","volume":"18","author":"Sung","year":"2004","journal-title":"FASEB J."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0700","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/BF02189542","article-title":"Vitamin B12-induced reduction of platelet monoamine oxidase activity in patients with dementia and pernicious anaemia","volume":"240","author":"Regland","year":"1991","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0705","first-page":"426","article-title":"Treatment of alzheimer-type dementia with intravenous mecobalamin","volume":"14","author":"Ikeda","year":"1992","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0710","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s10545-014-9701-z","article-title":"Innovative strategies to treat protein misfolding in inborn errors of metabolism: pharmacological chaperones and proteostasis regulators","volume":"37","author":"Muntau","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0715","doi-asserted-by":"crossref","first-page":"7207","DOI":"10.1073\/pnas.92.16.7207","article-title":"Pharmacological modulation of heat shock factor 1 by antiinflammatory drugs results in protection against stress-induced cellular damage","volume":"92","author":"Lee","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0720","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/95.12.845","article-title":"First proteasome inhibitor approved for multiple myeloma","volume":"95","author":"Twombly","year":"2003","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0725","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.cell.2008.06.037","article-title":"Chemical and biological approaches synergize to ameliorate protein-folding diseases","volume":"134","author":"Mu","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0730","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/nsmb1210-1400","article-title":"Understanding of the Hsp90 molecular chaperone reaches new heights","volume":"17","author":"Vaughan","year":"2010","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0735","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/j.bmcl.2007.01.017","article-title":"A non-toxic Hsp90 inhibitor protects neurons from abeta-induced toxicity","volume":"17","author":"Ansar","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0740","doi-asserted-by":"crossref","first-page":"188","DOI":"10.2174\/138920110790909650","article-title":"Induction of molecular chaperones as a therapeutic strategy for the polyglutamine diseases","volume":"11","author":"Nagai","year":"2010","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0745","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2174\/1567205011310040008","article-title":"Autophagy enhancer carbamazepine alleviates memory deficits and cerebral amyloid-β pathology in a mouse model of Alzheimer's Disease","volume":"10","author":"Li","year":"2013","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0750","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/cge.13088","article-title":"Protein misfolding diseases: prospects of pharmacological treatment","volume":"93","author":"G\u00e1mez","year":"2018","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0755","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.tem.2004.05.003","article-title":"Pharmacological chaperones: potential treatment for conformational diseases","volume":"15","author":"Bernier","year":"2004","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0760","doi-asserted-by":"crossref","first-page":"9629","DOI":"10.1073\/pnas.1121005109","article-title":"Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade","volume":"109","author":"Bulawa","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0765","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/cmdc.202100147","article-title":"Identification of natural products as potential pharmacological chaperones for protein misfolding diseases","volume":"16","author":"Sharma","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0770","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/2051-5960-1-79","article-title":"Molecular chaperones and protein folding as therapeutic targets in Parkinson\u2019s disease and other synucleinopathies","volume":"1","author":"Ebrahimi-Fakhari","year":"2013","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0775","doi-asserted-by":"crossref","first-page":"12058","DOI":"10.1038\/ncomms12058","article-title":"Pharmacological chaperone reshapes the energy landscape for folding and aggregation of the prion protein","volume":"7","author":"Gupta","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0780","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1128\/AAC.50.3.1034-1044.2006","article-title":"Potent antiscrapie activities of degenerate phosphorothioate oligonucleotides","volume":"50","author":"Kocisko","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0785","doi-asserted-by":"crossref","first-page":"12117","DOI":"10.1073\/pnas.95.21.12117","article-title":"Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines","volume":"95","author":"Caughey","year":"1998","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0790","doi-asserted-by":"crossref","first-page":"17610","DOI":"10.1073\/pnas.1009062107","article-title":"Pharmacological chaperone for the structured domain of human prion protein","volume":"107","author":"Nicoll","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0795","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-med-041217-010829","article-title":"Therapeutic antisense oligonucleotides are coming of age","volume":"70","author":"Bennett","year":"2019","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0800","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/brain\/awab423","article-title":"Antisense therapies in neurological diseases","volume":"145","author":"Brunet de Courssou","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0805","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103691","article-title":"Antisense oligonucleotides for Alzheimer\u2019s disease therapy: from the mRNA to miRNA paradigm","volume":"74","author":"Grabowska-Pyrzewicz","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0810","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.3233\/JAD-131883","article-title":"Central and peripheral administration of antisense oligonucleotide targeting amyloid-\u03b2 protein precursor improves learning and memory and reduces neuroinflammatory cytokines in Tg2576 (A\u03b2PPswe) mice","volume":"40","author":"Farr","year":"2014","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0815","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag0481","article-title":"Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy","volume":"9","author":"DeVos","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0820","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1080\/13506129.2016.1191458","article-title":"Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides","volume":"23","author":"Ackermann","year":"2016","journal-title":"Amyloid"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0825","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.neurobiolaging.2022.03.011","article-title":"ApoE4 reduction: an emerging and promising therapeutic strategy for Alzheimer\u2019s disease","volume":"115","author":"Li","year":"2022","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0830","article-title":"Molecular mechanisms of amyloid disaggregation","author":"Low","year":"2021","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0835","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.cell.2013.11.047","article-title":"Potentiated Hsp104 variants antagonize diverse proteotoxic misfolding events","volume":"156","author":"Jackrel","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0840","doi-asserted-by":"crossref","first-page":"39374","DOI":"10.1038\/srep39374","article-title":"Structure of crenezumab complex with A\u03b2 shows loss of \u03b2-hairpin","volume":"6","author":"Ultsch","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0845","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1021\/cn400051e","article-title":"Tanshinones inhibit amyloid aggregation by amyloid-\u03b2 peptide, disaggregate amyloid fibrils, and protect cultured cells","volume":"4","author":"Wang","year":"2013","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0850","doi-asserted-by":"crossref","first-page":"7992","DOI":"10.1038\/srep07992","article-title":"Brazilin inhibits amyloid \u03b2-protein fibrillogenesis, remodels amyloid fibrils and reduces amyloid cytotoxicity","volume":"5","author":"Du","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0855","doi-asserted-by":"crossref","first-page":"5764","DOI":"10.3390\/nu7075246","article-title":"Ferulic acid: a hope for Alzheimer\u2019s disease therapy from plants","volume":"7","author":"Sgarbossa","year":"2015","journal-title":"Nutrients"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0860","doi-asserted-by":"crossref","DOI":"10.1111\/jfbc.13936","article-title":"Neuroprotective potential of berberine in modulating Alzheimer\u2019s disease via multiple signaling pathways","volume":"45","author":"Akbar","year":"2021","journal-title":"J. Food Biochem."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0865","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2021.109077","article-title":"Inhibition and disruption of amyloid formation by the antibiotic levofloxacin: a new direction for antibiotics in an era of multi-drug resistance","volume":"714","author":"Khan","year":"2021","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0870","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1021\/acschemneuro.2c00371","article-title":"Moxifloxacin disrupts and attenuates A\u03b242 fibril and oligomer formation: plausibly repositioning an antibiotic as therapeutic against Alzheimer\u2019s Disease","volume":"13","author":"Khan","year":"2022","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0875","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/13506129.2011.582902","article-title":"The generic amyloid formation inhibition effect of a designed small aromatic \u03b2-breaking peptide","volume":"18","author":"Frydman-Marom","year":"2011","journal-title":"Amyloid"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0880","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41598-017-18443-2","article-title":"Mechanistic insights into remodeled Tau-derived PHF6 peptide fibrils by Naphthoquinone-Tryptophan hybrids","volume":"8","author":"KrishnaKumar","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0885","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/s42003-020-01216-5","article-title":"Tryptophan-galactosylamine conjugates inhibit and disaggregate amyloid fibrils of A\u03b242 and hIAPP peptides while reducing their toxicity","volume":"3","author":"Paul","year":"2020","journal-title":"Commun. Biol."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0890","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/s41565-018-0179-y","article-title":"Graphene quantum dots prevent \u03b1-synucleinopathy in Parkinson\u2019s disease","volume":"13","author":"Kim","year":"2018","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0895","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1021\/acschemneuro.8b00441","article-title":"Hydroxylated single-walled carbon nanotubes inhibit A\u03b2 42 fibrillogenesis, disaggregate mature fibrils, and protect against A\u03b2 42 -induced cytotoxicity","volume":"10","author":"Liu","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0900","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1039\/C9TB00162J","article-title":"Dual effect of chitosan-based nanoparticles on the inhibition of \u03b2-amyloid peptide aggregation and disintegration of the preformed fibrils","volume":"7","author":"Jha","year":"2019","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0905","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.amjmed.2022.01.002","article-title":"Developing therapy for transthyretin amyloidosis","volume":"135","author":"Campbell","year":"2022","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0910","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1007\/s10072-021-05550-2","article-title":"Zonisamide in Parkinson\u2019s disease: a current update","volume":"42","author":"Goel","year":"2021","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0915","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jagp.2019.09.009","article-title":"Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer\u2019s dementia: two 12-week, randomized, double-blind, placebo-controlled trials","volume":"28","author":"Grossberg","year":"2020","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0920","article-title":"Probing gut-brain links in Alzheimer\u2019s disease with rifaximin","volume":"8","author":"Suhocki","year":"2022","journal-title":"Alzheimer\u2019s Dement. Transl. Res. Clin. Interv."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0925","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/14728214.2020.1808621","article-title":"Anti-amyloid-\u03b2 protein agents for the treatment of Alzheimer\u2019s disease: an update on emerging drugs","volume":"25","author":"Lozupone","year":"2020","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0930","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13063-019-3259-x","article-title":"Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer\u2019s disease: study protocol for a randomised controlled trial (ELAD study)","volume":"20","author":"Femminella","year":"2019","journal-title":"Trials"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0935","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-051343","article-title":"Repurposing bromocriptine for A\u03b2 metabolism in Alzheimer\u2019s disease (REBRAnD) study: randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer\u2019s disease","volume":"11","author":"Kondo","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0940","article-title":"Targeted delivery of montelukast for treatment of Alzheimer\u2019s disease","author":"Datusalia","year":"2021","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0945","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.01688","article-title":"An updated review of randomized clinical trials testing the improvement of cognitive function of ginkgo biloba extract in healthy people and Alzheimer\u2019s patients","volume":"10","author":"Liu","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0950","doi-asserted-by":"crossref","DOI":"10.3390\/nu13020537","article-title":"Potential of caffeine in Alzheimer\u2019s disease-a review of experimental studies","volume":"13","author":"Londzin","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0955","doi-asserted-by":"crossref","first-page":"936","DOI":"10.5114\/aoms.2019.85463","article-title":"Resveratrol and cognitive decline: a clinician perspective","volume":"15","author":"Cicero","year":"2019","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0960","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.2174\/1568026620666200325110444","article-title":"Preclinical and clinical studies on bryostatins, a class of marine-derived protein kinase C modulators: a mini-review","volume":"20","author":"Raghuvanshi","year":"2020","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0965","article-title":"Trehalose against Alzheimer\u2019s disease: insights into a potential therapy","volume":"42","author":"Khalifeh","year":"2020"},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0970","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ana.26259","article-title":"Promise of nucleic acid therapeutics for amyotrophic lateral sclerosis","volume":"91","author":"Ito","year":"2022","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0975","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1208760","article-title":"Safety and efficacy of RNAi therapy for transthyretin amyloidosis","volume":"369","author":"Coelho","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2022.11.031_bb0980","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13195-019-0559-z","article-title":"Gantenerumab reduces amyloid-\u03b2 plaques in patients with prodromal to moderate Alzheimer\u2019s disease: a PET substudy interim analysis","volume":"11","author":"Klein","year":"2019","journal-title":"Alzheimers Res. Ther."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813022025806?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813022025806?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T09:40:47Z","timestamp":1758879647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813022025806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":196,"alternative-id":["S0141813022025806"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2022.11.031","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Protein misfolding and related human diseases: A comprehensive review of toxicity, proteins involved, and current therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2022.11.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}